Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for 10x Genomics's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TXG vs HNGE, WAY, TEM: Total Payout Ratio Comparison
For the Health Information Services subindustry, 10x Genomics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Total Payout Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a Total Payout Ratio of 0.00 as of Aug. 08, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on 10x Genomics and its competitors.
Is 10x Genomics' Total Payout Ratio too high?
10x Genomics' current Total Payout Ratio is 0.00. Overall, 10x Genomics has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Total Payout Ratio compare to HNGE and WAY?
10x Genomics' Total Payout Ratio of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Healthcare Providers & Services company?
A good Total Payout Ratio depends on the Healthcare Providers & Services industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on 10x Genomics and its competitors. 10x Genomics's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.83, compared to a current price of $52.15 — trading 177% above its estimated fair value. The current Total Payout Ratio is 0.00. 10x Genomics' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For 10x Genomics (TXG), the current Total Payout Ratio is 0.00 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $52.15 is trading 177% above its estimated GF Value™ of $18.83.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Total Payout Ratio: 0.00
GF Value™: $18.83 vs. price of $52.15 (177% above fair value)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
58GF Score
Get the complete analysis for TXG
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
